Current review of hemp‐based medicines in dogs

• Published in: Journal of veterinary pharmacology and therapeutics 2021-11, Vol.44 (6), p.870-882
• Main Authors: R C Coelho, Maria Paula, de O P Leme, Fabiola, A Moreira, Fabricio, E M T Branco, Stephanie, M Melo, Marilia, G de Melo, Eliane
• Format: Article
• Language: English
• Subjects: CBD; efficacy; pharmacodynamics; pharmacokinetics; safety; THC
• ISSN: 0140-7783; 1365-2885
• DOI: 10.1111/jvp.13016

Medical use of Cannabis (or hemp) began thousands of years ago. In the 20th century, mechanisms of action were demonstrated with the discovery of its active substances, the phytocannabinoids, and its pharmacological targets, the endocannabinoid system. This system is composed of receptors, endogenous substances, and enzymes, and it participates in the modulation of physiological mechanisms in several species, including dogs. Studies indicate that changes in this system may contribute to the genesis of some diseases. Therefore, the use of substances that act on its components may help in the treatment of these diseases. The main phytocannabinoids described are Δ9−tetrahydrocannabinol (THC) and cannabidiol (CBD). In humans, the benefits of using CBD in several diseases have been demonstrated. The popularization of this type of treatment has also reached veterinary medicine, which on one hand was related to an increase in adverse event records, but on the other also allowed reports of anecdotal evidences of its effectiveness and safety in animals. Clinical studies published so far indicate that the use of CBD in dogs can be safe at given doses and can contribute to osteoarthritis and idiopathic epilepsy treatments. Clinical and pre‐clinical studies and case reports were reviewed in this report to identify the main characteristics of hemp‐based therapies in dogs, including its pharmacokinetics, pharmacodynamics, safety, and efficacy in the treatment of diseases.